Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Other Working Capital Changes (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Other Working Capital Changes for 6 consecutive years, with $781000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 116.48% to $781000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 million, a 189.25% increase, with the full-year FY2025 number at $3.2 million, up 189.25% from a year prior.
  • Other Working Capital Changes was $781000.0 for Q4 2025 at GeneDx Holdings, up from -$6.5 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $12.0 million in Q2 2025 to a low of -$11.0 million in Q3 2021.
  • A 5-year average of $63800.0 and a median of $816500.0 in 2024 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: crashed 3476.02% in 2021, then surged 1309.62% in 2025.
  • GeneDx Holdings' Other Working Capital Changes stood at $3.2 million in 2021, then crashed by 286.45% to -$5.9 million in 2022, then rose by 26.49% to -$4.3 million in 2023, then fell by 9.75% to -$4.7 million in 2024, then soared by 116.48% to $781000.0 in 2025.
  • Per Business Quant, the three most recent readings for WGS's Other Working Capital Changes are $781000.0 (Q4 2025), -$6.5 million (Q3 2025), and $12.0 million (Q2 2025).